GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Net Income Including Noncontrolling Interests

MindBio Therapeutics (XCNQ:MBIO) Net Income Including Noncontrolling Interests : C$-3.16 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

MindBio Therapeutics's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2024 was C$0.07 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 was C$-3.16 Mil.


MindBio Therapeutics Net Income Including Noncontrolling Interests Historical Data

The historical data trend for MindBio Therapeutics's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Net Income Including Noncontrolling Interests Chart

MindBio Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Net Income Including Noncontrolling Interests
- -6.73 -3.82

MindBio Therapeutics Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.28 -3.03 -0.16 -0.04 0.07

MindBio Therapeutics Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-3.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MindBio Therapeutics Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


MindBio Therapeutics (XCNQ:MBIO) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Net Income Including Noncontrolling Interests
Traded in Other Exchanges
Address
91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000
MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.

MindBio Therapeutics (XCNQ:MBIO) Headlines

From GuruFocus